SORCI, Guglielmo
 Distribuzione geografica
Continente #
NA - Nord America 7.217
EU - Europa 5.569
AS - Asia 5.356
SA - Sud America 980
AF - Africa 134
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 14
Totale 19.285
Nazione #
US - Stati Uniti d'America 7.034
SG - Singapore 2.355
IT - Italia 1.134
UA - Ucraina 898
BR - Brasile 784
HK - Hong Kong 768
CN - Cina 757
IE - Irlanda 732
RU - Federazione Russa 636
SE - Svezia 576
VN - Vietnam 429
DE - Germania 350
FR - Francia 287
KR - Corea 274
FI - Finlandia 235
GB - Regno Unito 206
IN - India 128
TR - Turchia 128
BD - Bangladesh 113
NL - Olanda 93
CA - Canada 80
RO - Romania 80
AT - Austria 76
IQ - Iraq 67
PL - Polonia 58
AR - Argentina 57
MX - Messico 56
JP - Giappone 48
CH - Svizzera 45
ZA - Sudafrica 43
CO - Colombia 40
PH - Filippine 38
PK - Pakistan 38
ES - Italia 34
UZ - Uzbekistan 31
EC - Ecuador 30
BE - Belgio 28
ID - Indonesia 28
VE - Venezuela 25
MA - Marocco 21
CZ - Repubblica Ceca 18
SA - Arabia Saudita 18
LB - Libano 16
MY - Malesia 16
JM - Giamaica 14
CL - Cile 13
JO - Giordania 12
PY - Paraguay 12
TN - Tunisia 12
EG - Egitto 11
EU - Europa 11
LT - Lituania 11
AU - Australia 10
AZ - Azerbaigian 10
KE - Kenya 10
GR - Grecia 9
IR - Iran 9
MD - Moldavia 9
SK - Slovacchia (Repubblica Slovacca) 9
AE - Emirati Arabi Uniti 8
BG - Bulgaria 8
PE - Perù 8
CR - Costa Rica 7
DZ - Algeria 7
IL - Israele 7
ET - Etiopia 6
OM - Oman 6
TH - Thailandia 6
TW - Taiwan 6
BA - Bosnia-Erzegovina 5
BO - Bolivia 5
DO - Repubblica Dominicana 5
KG - Kirghizistan 5
KH - Cambogia 5
NP - Nepal 5
UY - Uruguay 5
AL - Albania 4
HU - Ungheria 4
KZ - Kazakistan 4
LV - Lettonia 4
NI - Nicaragua 4
NZ - Nuova Zelanda 4
PA - Panama 4
BY - Bielorussia 3
DK - Danimarca 3
GE - Georgia 3
GT - Guatemala 3
KW - Kuwait 3
PS - Palestinian Territory 3
RS - Serbia 3
SN - Senegal 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
BH - Bahrain 2
CY - Cipro 2
GA - Gabon 2
HR - Croazia 2
ME - Montenegro 2
MG - Madagascar 2
MN - Mongolia 2
Totale 19.245
Città #
Singapore 1.773
Chandler 870
Hong Kong 754
Dublin 728
San Jose 623
Jacksonville 492
Ashburn 481
San Mateo 418
Perugia 305
Boardman 296
Santa Clara 274
Moscow 238
Seoul 202
Wilmington 188
Medford 186
Princeton 185
Lauterbourg 178
Beijing 154
Dong Ket 140
Ann Arbor 129
The Dalles 121
Andover 114
Los Angeles 114
Ho Chi Minh City 107
Altamura 100
New York 92
Munich 87
Piscataway 79
Izmir 68
Lawrence 68
São Paulo 68
Bucharest 64
Des Moines 61
Vienna 59
Hanoi 55
Saint Petersburg 55
Dearborn 53
Norwalk 53
Redmond 52
Shanghai 50
Helsinki 47
Orem 44
Falls Church 41
Council Bluffs 39
Tokyo 37
Montreal 34
Rome 34
Turin 33
Philadelphia 32
Bologna 31
Warsaw 31
Rio de Janeiro 30
Dallas 29
Shenzhen 29
Woodbridge 28
Brussels 27
Johannesburg 27
Boston 26
Phoenix 24
Amsterdam 23
Atlanta 23
Chicago 23
Houston 23
Milan 23
Baghdad 22
Brooklyn 22
London 22
Stockholm 22
Chennai 21
Denver 21
Falkenstein 21
Frankfurt am Main 21
Turku 21
Nuremberg 19
Seongnam-si 19
Brasília 17
Da Nang 17
Guangzhou 17
Belo Horizonte 16
Manchester 16
Tashkent 16
Lahore 15
Redwood City 15
San Francisco 15
Toronto 15
Florence 14
Ankara 13
Cebu City 13
Dhaka 13
Tijuana 13
Mumbai 12
Olomouc 12
Parma 12
Quito 12
Auburn Hills 11
Haiphong 11
Istanbul 11
Porto Alegre 11
Amman 10
Baku 10
Totale 11.440
Nome #
Beneficial effects of horsetail (Equisetum arvense) in experimental models of sarcopenia and osteoporosis 275
Le proteine S100 267
Artesunate induces ROS- and p38 MAPK-mediated apoptosis and counteracts tumor growth in vivo in embryonal rhabdomyosarcoma cells 203
Pharmacological targeting of the receptor for advanced glycation end-products (RAGE) to counteract cancer cachexia 198
An HMGB1/RAGE/p38 MAPK/Myogenin Axis Modulates Pax7 Expression in Myoblasts by Both Transcriptional and Post-Transcriptional Mechanisms 180
Histological muscle characterization in hypertrophied Marchigiana cattle breed 174
Intraperitoneal injection of microencapsulated Sertoli cells restores muscle morphology and performance in dystrophic mice 173
Artesunate induces ROS-mediated apoptosis and counteracts tumor growth in vivo in embryonal rhabdomyosarcoma cells. 167
IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII 161
Targeting RAGE prevents muscle wasting and prolongs survival in cancer cachexia 152
Identification of natural products able to counteract the formation of advanced glycation end-products (AGEs) sustaining muscle atrophy 149
RAGE in the pathophysiology of skeletal muscle. 147
Extracellular S100B causes nuclear translocation of NF-?B in rat L6 myoblasts likely by binding to RAGE 145
Differential expression of S100B protein and RAGE in young and aged human satellite cells. 144
Biological effects of astrocyte-derived S100-beta protein on BV-2 microglial cell line 142
Generation of an mdx/Ager–/– double mutant mouse. Preliminary data on skeletal muscle architecture. 141
Equisetum arvense standardized extract hinders age-related sarcopenia 139
S100B protein regulates myoblast and macrophage functions in skeletal muscle regeneration 138
Absence of RAGE in an animal experimental model of Duchenne muscular dystrophy results in reduced muscle necrosis and inflammation 138
A braking circuit between pathogen- and danger-sensing signaling pathways restrains lung inflammation: role of S100B protein, RAGE and Toll-like receptors. 136
Sertoli cells protect C2C12 myotubes against atrophy and induce utrophin expression in canine and human dystrophic myotubes. 136
Toward the identification of receptor for advanced glycation end-products (RAGE) as a muscle biomarker of cancer cachexia. 136
Amphoterin-induced myogenic differentiation of RAGE-transfected rhabdomyosarcoma TE671 cells 135
Cellular and molecular mechanisms of sarcopenia: the S100B perspective 135
Activation of RAGE in myoblasts and rhabdomyosarcoma cells results in downregulation of Pax7 expression 134
Effect of recombinant murine tumor necrosis factor on the generation of natural killer cells in bone marrow cultures 134
Natural products to counteract muscle atrophy 133
Ablation of RAGE (receptor for advanced glycation end-products) translates into reduced tumorigenic and cachectic potential in LLC-tumor bearing mice 131
An ultrastructural study of Sertoli cells inside alginate microcapsules. 130
RAGE signalling in myoblasts and embryonal rhabdomyosarcoma cells represses Pax7 expression via p38 MAPK-dependent induction of myogenin. 129
Effects of intraperitoneal injection of microencapsulated Sertoli cells on chronic and presymptomatic dystrophic mice 129
Screening of 100 plant extracts for the development of a herbal product effective against muscle atrophy 129
Aged vs young human satellite cells: altered expression of S100B and RAGE, and defective ability in conditioning the medium contribute to impaired myogenic potential. 128
Sertoli cell-secreted factors have promyogenic and antifibrotic properties on human DMD myoblasts with different mutations. 128
RAGE and its ligands, S100B and HMGB1, are molecular determinants of cancer-induced muscle wasting. 127
The calcium-modulated proteins, S100A1 and S100B, as potential regulators of the dynamics of the type III intermediate filaments 125
S100B protein, a damage-associated molecular pattern protein in the brain and heart, and beyond 125
Amphoterin stimulates myogenesis and counteracts the anti-myogenic factors, bFGF and S100B, via RAGE binding 124
Targeting RAGE as a potential therapeutic approach to Duchenne muscular dystrophy 124
"Neuron-specific" protein gene product 9.5 (PGP 9.5) is also expressed in glioma cell lines and its expression depends on cellular growth 121
RAGE expression in rhabdomyosarcoma cells results in reduced proliferation, migration, and invasiveness in vitro and tumor growth in vivo 120
Hypoxia Promotes Danger-mediated Inflammation via Receptor for Advanced Glycation End Products in Cystic Fibrosis 120
Histological Muscle Characterization in Hypertrophied Marchigiana Beef Cattle Breed 119
Implication of RAGE and Amphoterin in Myogenesis 118
Different intrinsic properties of young and aged human satellite cells. 118
Glial S100B protein in neuroprotection and neurodegeneration 116
Appropriate levels of extracellular S100B protein in injured muscle are required for correct muscle regeneration. 114
Involvement of a RAGE/p38MAPK/myogenin axis in cancer cachexia. 111
Association of S100B with intermediate filaments and microtubules in glial cells 110
Mdx/Ager–/– mice show reduced muscle necrosis and inflammation compared with mdx mice 110
The role of a mindful movement-based program (Movimento Biologico) in health promotion: results of a pre-post intervention study 109
S100B retards the biochemical differentiation of myoblasts and their fusion into myotubes 109
KYMASIN UP Natural Product Inhibits Osteoclastogenesis and Improves Osteoblast Activity by Modulating Src and p38 MAPK 108
S100B neuroprotective effect against ßamyloid-driven neurotoxicity 107
Employment of Microencapsulated Sertoli Cells as a New Tool to Treat Duchenne Muscular Dystrophy 107
Receptor for advanced glycation end-products (RAGE) as a biomarker of muscle wasting in cancer conditions 107
Microencapsulated Sertoli cells sustain myoblast proliferation without affecting the myogenic potential. In vitro data 107
Synergistic regulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through RAGE activation 106
Young and Aged Human Muscle Satellite Cells Show Differential Expression of S100B Protein and RAGE. 106
Role of calcium-binding proteins (S100B, annexin II2-p112, annexin VI) in the regulation of GFAP intermediate filament dynamics 106
Transplantation of microencapsulated Sertoli cells: a new potential antiinflammatory approach to Duchenne muscular dystrophy (DMD). 106
Beneficial effects of horsetail (Equisetum arvense) in in vitro models of sarcopenia and osteoporosis 105
S100B inhibits myotube formation 105
S100B causes apoptosis in a myoblast cell line in a RAGE-independent manner 105
The effects of microgravity on human skeletal muscle regeneration. 105
Hyperactivated rage in comorbidities as a risk factor for severe covid-19—the role of rage-ras crosstalk 105
Effects of S100B and S100A1 on cytoplasmic microtubules in triton-cytoskeletons from cell lines 104
RAGE engagement in myoblasts modulates proliferation, apoptosis, adhesiveness, migration and invasiveness 104
RAGE signaling in myoblasts and rhabdomyosarcoma cells causes downregulation of Pax7 expression via p38 MAPK activation and upregulation of myogenin expression 103
S100B protein in tissue development, repair and regeneration 103
Equisetum arvense standardized dried extract hinders age-related osteosarcopenia. 102
Genetically-determined hyperfunction of the S100B/RAGE axis is a risk factor for aspergillosis in stem cell transplant recipients 102
Immunocytochemical detection of S100A1 and S100B in fused myotubes and related immunochemical analyses 102
The danger signal S100B integrates pathogen- and danger-sensing pathways to restrain inflammation 102
Causes of elevated serum levels of S100B protein in athletes 102
Identification of Withania somnifera-Silybum marianum-Trigonella foenum-graecum Formulation as a Nutritional Supplement to Contrast Muscle Atrophy and Sarcopenia 102
The calcium-modulated proteins, S100A1 and S100B, as potential regulators of the dynamics of type III intermediate filaments 101
Immunocytochemistry of S100B, annexin V and annexin VI in glial and microglial cells. 101
Cellular growth state-dependent expression of annexin V in glioma cell lines. 101
Do porcine Sertoli cells represent an opportunity for Duchenne muscular dystrophy? 101
Colocalization of S100B with intermediate filaments and microtubules in L6 myoblasts and U251 glial cells. 100
Caveolins and cavins in muscle-derived tumours. 100
Levels of S100B protein drive the reparative process in acute muscle injury and muscular dystrophy 99
Use of Sertoli cells to treat DMD patients is supported by their immunomodulatory rather than immunosuppressive effect 99
Effects of extracellular S100B, a calcium-binding protein of the EF-hand type, on a skeletal muscle cell line 98
Defective RAGE activity in embryonal rhabdomyosarcoma cells results in high PAX7 levels that sustain migration and invasiveness 98
Is the binding of S100A1 (and S100B) to synapsin I physiologically relevant? 98
The calcium-modulated proteins, S100B and S100A1, disassemble cytoplasmic microtubules in situ. An in vitro study using triton-cytoskeletons from cell lines 97
Functions of S100 proteins 97
Complex regulatory effects of extracellular S100B on myoblast differentiation: S100B activates quiescent myoblats and satellite cells 96
Effects of deletion of RAGE in muscle regeneration: preliminary observations. 96
S100B protein differentially regulates myoblast differentiation via direct binding to RAGE and bFGF-mediated activation of FGFR1 in low-density and high-density cultures, respectively 95
S100B engages RAGE or bFGF/FGFR1 in myoblasts depending on its own concentration and myoblast density. Implications for muscle regeneration 95
Novel data support the use of microencapsulated Sertoli cells as a potential treatment of DMD patients. 95
Reductive stress in striated muscle cells 95
S100B and S100A1 disassemble cytoplasmic microtubules in triton-cytoskeletons from glioma and myoblast cells 94
Detection of membrane-bound guanylate cyclase activity in rat C6 glioma cells at different growth states following activation by natriuretic peptides 94
Human muscle satellite cells show age-related differential expression of S100B protein and RAGE. 94
S100 proteins in obesity: liaisons dangereuses 94
Opposing regulatory roles of S100B and amphoterin in myogenic differentiation: RAGE-dependence of amphoterin stimulatory effects vs. RAGE-independence of S100B inhibitory effects 93
Totale 12.178
Categoria #
all - tutte 79.767
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 79.767


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.692 32 305 42 123 61 24 31 496 22 56 202 298
2022/20232.622 218 375 43 219 228 288 7 137 970 10 91 36
2023/20241.242 62 98 53 51 53 32 319 41 149 40 153 191
2024/20253.476 69 323 236 152 480 139 275 307 556 173 561 205
2025/20266.682 438 383 291 927 850 631 1.139 348 711 529 321 114
2026/2027189 189 0 0 0 0 0 0 0 0 0 0 0
Totale 19.683